Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations-Reference-Cited by-同舟云学术

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

Published:2018-06-27 Issue:7712 Volume:559 Page:125-129
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Intlekofer Andrew M.,Shih Alan H.,Wang Bo,Nazir Abbas,Rustenburg Ariën S.,Albanese Steven K.,Patel Minal,Famulare Christopher,Correa Fabian M.,Takemoto Naofumi,Durani Vidushi,Liu Hui,Taylor Justin,Farnoud Noushin,Papaemmanuil Elli,Cross Justin R.,Tallman Martin S.,Arcila Maria E.,Roshal Mikhail,Petsko Gregory A.,Wu Bin,Choe Sung,Konteatis Zenon D.,Biller Scott A.,Chodera John D.,Thompson Craig B.,Levine Ross L.,Stein Eytan M.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41586-018-0251-7.pdf

Reference25 articles.

1. Losman, J. A. & Kaelin, W. G. Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 27, 836–852 (2013).

2. Ley, T. J. et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 456, 66–72 (2008).

3. Ward, P. S. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17, 225–234 (2010).

4. Gross, S. et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J. Exp. Med. 207, 339–344 (2010).

5. Losman, J. A. et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621–1625 (2013).

Cited by 232 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in pathogenesis research and challenges in treatment development for acute myeloid leukemia;International Journal of Hematology;2024-09-03

2. Tricarboxylic Acid Cycle Relationships with Non-Metabolic Processes: A Short Story with DNA Repair and Its Consequences on Cancer Therapy Resistance;International Journal of Molecular Sciences;2024-08-21

3. Precision medicine in AML: overcoming resistance;International Journal of Hematology;2024-08-01

4. Treatment of IDH-mutant glioma in the INDIGO era;npj Precision Oncology;2024-07-19

5. Mechanisms of Resistance to Targeted Therapies in AML;Annual Review of Cancer Biology;2024-06-12